Abstract
The aim was to evaluate the clinical utility of D-dimer POC assay analyzers to rule out the diagnosis of PTE in adult patients diagnosed with COVID-19. Systematic review and meta-analysis. The evaluated technology was the Point-of-Care D-dimer assay analyzer. To combine the effect estimates whose measure was the difference between the means, the random effect model was used. We included 10 studies that evaluated 14 Point-of-Care analyzers compared to the Enzyme Linked Immunosorbent Assay assay. All Point-of-Care analyzers evaluated showed sensitivity and NPV greater than 95 and 97%, respectively, with an average return time of 95 minutes. Evidence suggests that the use of Point-of-Care analyzers for D-dimer is clinically useful to rule out cases of pulmonary thromboembolism and other thromboembolic complications in patients with COVID-19 treated in the emergency room or in primary care units.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.